グセルクマブによる2年間の治療での臨床的有効性と画像的進行との関連: バイオ未治療で活動性乾癬性関節炎患者を対象としたフェーズ3無作為化二重盲検プラセボ対照試験結果
RMD Open. 2023 doi: 10.1136/rmdopen-2022-002789
Data from this paper provides a robust analysis of radiographic progression through 2 years in a phase 3 study of guselkumab in patients with PsA. This study sought to evaluate the relationship between radiographic progression and clinical outcomes in post hoc analyses of patients with PsA receiving up to 2 years of guselkumab therapy in DISCOVER-2.
Data also highlight the importance of addressing structural damage in a timely manner to optimise long-term patient outcomes, including preservation of function.
Keywords:
